Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536215

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536215

Phenylketonuria Treatment

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Phenylketonuria Treatment Market to Reach US$1.6 Billion by 2030

The global market for Phenylketonuria Treatment estimated at US$975.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Palynziq Drug, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$918.2 Million by the end of the analysis period. Growth in the Kuvan Drug segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$265.6 Million While China is Forecast to Grow at 11.2% CAGR

The Phenylketonuria Treatment market in the U.S. is estimated at US$265.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$343.9 Million by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Phenylketonuria Treatment Market - Key Trends and Drivers Summarized

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is necessary for the metabolism of the amino acid phenylalanine. When PAH is deficient or absent, phenylalanine accumulates in the blood and brain, leading to severe cognitive impairments and neurological issues if left untreated. The cornerstone of PKU management has traditionally been a strict, lifelong diet low in phenylalanine, which involves the exclusion of high-protein foods and the inclusion of specially formulated medical foods and phenylalanine-free amino acid supplements. Early diagnosis through newborn screening programs has been critical in preventing the severe outcomes associated with untreated PKU, allowing for the timely initiation of dietary management and close monitoring of phenylalanine levels.

In recent years, advances in PKU treatment have expanded beyond dietary management, providing new therapeutic options that improve patient outcomes and quality of life. One significant development is the use of pharmacological treatments such as sapropterin dihydrochloride, a synthetic form of the cofactor tetrahydrobiopterin (BH4), which can enhance the residual activity of PAH in some patients with mild to moderate PKU. Additionally, pegvaliase, an enzyme substitution therapy, has been approved for adults with PKU who have uncontrolled blood phenylalanine levels despite dietary management. Pegvaliase works by breaking down phenylalanine in the bloodstream, offering a new avenue for those who struggle to maintain low phenylalanine levels through diet alone. Gene therapy and other innovative treatments are also under investigation, aiming to provide more permanent solutions by addressing the underlying genetic cause of PKU.

The growth in the phenylketonuria treatment market is driven by several factors. The increasing awareness and understanding of PKU among healthcare providers and patients have led to earlier and more accurate diagnoses, boosting the demand for effective treatments. Technological advancements and ongoing research have facilitated the development of new pharmacological therapies and innovative treatments, expanding the options available for PKU management. The rise of personalized medicine, which tailors treatments to individual genetic profiles, is also driving market growth by offering more targeted and effective therapies. Additionally, the expansion of newborn screening programs globally has increased the detection rates of PKU, further fueling the need for comprehensive treatment solutions. The growing availability of specialized medical foods and supplements, coupled with supportive healthcare policies and funding for rare disease treatments, are creating a favorable market environment. As these trends continue to evolve, the phenylketonuria treatment market is poised for significant growth, driven by advancements in medical science and a heightened focus on improving patient outcomes.

Select Competitors (Total 86 Featured) -

  • Ajinomoto Cambrooke, Inc.
  • American Gene Technologies Inc.
  • Arla Foods Ingredients Group P/S
  • BioMarin Pharmaceutical, Inc.
  • Codexis, Inc.
  • Metropolis Healthcare Ltd.
  • Nestle Health Science SA
  • Nutricia
  • PTC Therapeutics
  • SOM Biotech
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical, Inc.
Show more
Product Code: MCP26674

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Phenylketonuria Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Understanding of PKU Expands Addressable Market Opportunity
    • Advances in Pharmacological Treatments Strengthen Business Case for PKU Management
    • Rise of Personalized Medicine Propels Growth in Tailored Therapeutics
    • Expansion of Newborn Screening Programs Generates Demand for Early Intervention
    • Development of Enzyme Substitution Therapies Drives Adoption of New Treatments
    • Innovative Gene Therapy Research Throws the Spotlight on Potential Cure for PKU
    • Technological Advancements in Medical Foods and Supplements Accelerate Market Growth
    • Growing Availability of Specialized Medical Foods Spurs Market Demand
    • Rising Investment in Rare Disease Research Generates New Opportunities
    • Focus on Long-Term Health Outcomes Strengthens Case for Comprehensive Treatment Plans
    • Integration of Telehealth Services in PKU Management Propels Market Growth
    • Increasing Prevalence of PKU and Early Diagnoses Generate Demand for Advanced Therapies
    • Advances in Biotechnology Facilitate Development of Next-Generation PKU Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Phenylketonuria Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Palynziq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kuvan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!